Study 14 of 25Tirzepatide literatureBMJ (Clinical research ed.)Top journal2026
Tirzepatide and cardiovascular outcomes.
Not reported in abstract.
Where it sits
this study against the rest of the tirzepatide corpus4
Preclinical · this one
15
Observational
1
Open-label
2
Randomised
3
Reviews
Summary and findings
Not reported in abstract.
How much of this paper we could read: title only (0.10). The feed gave us little more than the title, so our summary is thin. This says nothing about the study's quality — read the source. What this means →
2026
Background
Not reported in abstract.
Methods
Not reported in abstract.
Results
Not reported in abstract.
Interpretation
Not reported in abstract.
Limitations
Not reported in abstract.
Elsewhere in the Tirzepatide corpus
BDual GIP/GLP-1 Receptor Agonist Versus Selective GLP-1 Receptor Agonist in Patients Undergoing Primary Total Knee or Hip Arthroplastybiorxiv-preprint · At 2 years, tirzepatide exposure was associated with lower odds of mechanical complications (OR 0.64, 95% CI 0.42 to 0.96).HumanCTirzepatide preserves hematopoietic stem and progenitor cycling while remodeling inflammatory monocytes in obese micebiorxiv-preprint · Not reported in abstract.AnimalDThe GLP-1 Nutritional Paradox: A Structured Review with Novel Quantitative Frameworks for Sarcopenic Risk and Micronutrient Adequacy in GLP-1 Receptor Agonist Pharmacotherapybiorxiv-preprint · Mean body-weight reduction of 20.9% with tirzepatide in phase 3 trials.reviewBWeight Loss With Microdose Tirzepatide: Real-World Outcomes in Patients Initiating Treatment Below 2.5 mg Weeklybiorxiv-preprint · Mean body-weight loss was 6.10% (95% CI 4.60-7.60; n=8) in the 60-89-day window at a median 65.5 days.HumanCA near-infrared light-triggered platform for on-demand drug release in bone repair.Colloids and surfaces. B, Biointerfaces · 2026 · Bacterial inhibition rate of 99%.In vitroDFrom adiposity to multisystem morbidity: the case for weight loss as disease modification.The lancet. Diabetes & endocrinology · 2026—